title: Metabolomic evaluation of the response to endocrine therapy in patients with prostate cancer.
abstract: Timely evaluation of the response to endocrine therapy in patients with prostate cancer (PCa) may optimize treatment regimens and improve long-term prognosis. We used the liquid chromatography-mass spectrometry (LC-MS)-based metabolomic technique to identify serum biomarkers indicative of disease progression and therapeutic benefit. The mean serum levels of seven metabolites, including deoxycholic acid (DCA), glycochenodeoxycholate (GCDC), l-tryptophan, docosapentaenoic acid (DPA), arachidonic acid, deoxycytidine triphosphate, and pyridinoline, differed significantly between untreated PCa patients and healthy controls. In patients who did not develop castration-resistant prostate cancer (CRPC) for at least 2 years (good responders), these metabolite levels reverted to near healthy control levels during endocrine therapy. In contrast, the metabolite levels remained abnormal in patients who developed CRPC within 1 year (poorly responsive patients). Three of these biomarkers (DCA, GCDC, and DPA) are mainly involved in cholesterol metabolism, underscoring the importance of elevated cholesterol to PCa progression. These metabolites may serve as predictive biomarkers for assessing the therapeutic response of PCa patients to endocrine therapy.
authors.affiliation: Department of Urology, School of Pharmacy, Second Military Medical University, Shanghai, PR China; Department of Urology, the 411th Hospital of PLA, No. 15 East Jiangwan Road, Shanghai, PR China.
authors.forename: Gang
authors.initials: G
authors.lastname: Huang
authors.affiliation: School of Pharmacy, Second Military Medical University, Shanghai, PR China.
authors.forename: Xinru
authors.initials: X
authors.lastname: Liu
authors.affiliation: Department of Urology, School of Pharmacy, Second Military Medical University, Shanghai, PR China.
authors.forename: Li
authors.initials: L
authors.lastname: Jiao
authors.affiliation: Department of Urology, School of Pharmacy, Second Military Medical University, Shanghai, PR China.
authors.forename: Chuanliang
authors.initials: C
authors.lastname: Xu
authors.affiliation: School of Pharmacy, Second Military Medical University, Shanghai, PR China.
authors.forename: Zhongxiao
authors.initials: Z
authors.lastname: Zhang
authors.affiliation: Department of Urology, School of Pharmacy, Second Military Medical University, Shanghai, PR China.
authors.forename: Linhui
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of Urology, School of Pharmacy, Second Military Medical University, Shanghai, PR China.
authors.forename: Yun
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Urology, School of Pharmacy, Second Military Medical University, Shanghai, PR China.
authors.forename: Chun
authors.initials: C
authors.lastname: Yang
authors.affiliation: School of Pharmacy, Second Military Medical University, Shanghai, PR China. Electronic address: wdzhangy@hotmail.com.
authors.forename: Weidong
authors.initials: W
authors.lastname: Zhang
authors.affiliation: Department of Urology, School of Pharmacy, Second Military Medical University, Shanghai, PR China. Electronic address: sunyh@medmail.com.
authors.forename: Yinghao
authors.initials: Y
authors.lastname: Sun
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood; D006727:Hormone Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D055432:Metabolomics / Q000379:methods*; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy*; D011897:Random Allocation; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D006727:Hormone Antagonists
keywords: DCA; DPA; Endocrine therapy; GCDC; Metabolomics; Prostate cancer